Genetic Algorithms as a Tool for Dosing Guideline Optimization: Application to Intermittent Infusion Dosing for Vancomycin in Adults.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
14
01
2020
accepted:
05
04
2020
pubmed:
10
5
2020
medline:
12
8
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
This paper demonstrates the use of a genetic algorithm (GA) for the optimization of a dosing guideline. GAs are well-suited to derive combinations of doses and dosing intervals that go into a dosing guideline when the number of possible combinations rule out the calculation of all possible outcomes. GAs also allow for different constraints to be imposed on the optimization process to safeguard the clinical feasibility of the dosing guideline. In this work, we demonstrate the use of a GA for the optimization of intermittent vancomycin administration in adult patients. Constraints were placed on the dose strengths, the length of the dosing intervals, and the maximum infusion rate. In addition, flexibility with respect to the timing of the first maintenance dose was included in the optimization process. The GA-based optimal solution is compared with the Scottish Antimicrobial Prescribing Group vancomycin guideline.
Identifiants
pubmed: 32383808
doi: 10.1002/psp4.12512
pmc: PMC7239335
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
294-302Informations de copyright
© 2020 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Références
Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995
pubmed: 30333114
J Antimicrob Chemother. 2009 May;63(5):1050-7
pubmed: 19299472
Ann Pharmacother. 2011 May;45(5):687-9
pubmed: 21521857
J Antimicrob Chemother. 2016 Nov;71(11):3020-3025
pubmed: 27494905
J Pharm Pharmacol. 2019 Nov;71(11):1635-1644
pubmed: 31412422
Clin Pharmacokinet. 2019 Jun;58(6):767-780
pubmed: 30656565
Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):233-238
pubmed: 28834212
Nephron. 1976;16(1):31-41
pubmed: 1244564
J Pharmacokinet Pharmacodyn. 2006 Apr;33(2):195-221
pubmed: 16565924
J Clin Pharmacol. 2018 Sep;58(9):1131-1133
pubmed: 30024648
J Crit Care. 2013 Oct;28(5):710-6
pubmed: 23499418
Int J Infect Dis. 2012 Nov;16(11):e804-10
pubmed: 22917921
Antimicrob Agents Chemother. 2009 May;53(5):1863-7
pubmed: 19223642
Can J Hosp Pharm. 2012 May;65(3):180-7
pubmed: 22783028
J Infect Chemother. 2013 Jun;19(3):365-80
pubmed: 23673472
Interdiscip Perspect Infect Dis. 2013;2013:839456
pubmed: 24163693
J Antimicrob Chemother. 2016 Feb;71(2):471-9
pubmed: 26568565
J Pharmacokinet Pharmacodyn. 2018 Feb;45(1):127-137
pubmed: 29411198
J Antimicrob Chemother. 2020 Apr 11;:
pubmed: 32277830
Pharmacotherapy. 2011 May;31(5):441-8
pubmed: 21923425
Crit Care. 2019 Jun 21;23(1):228
pubmed: 31227005
Br J Clin Pharmacol. 2015 Jan;79(1):28-39
pubmed: 23772792
Sci Rep. 2018 Jun 26;8(1):9712
pubmed: 29946101
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
pubmed: 19106348
Crit Care. 2014 Dec 05;18(6):654
pubmed: 25475123
J Antimicrob Chemother. 2018 Nov 1;73(11):3081-3086
pubmed: 30203073